» Articles » PMID: 7923112

Expression of the Multidrug Resistance-associated Protein (MRP) Gene Correlates with Amplification and Overexpression of the N-myc Oncogene in Childhood Neuroblastoma

Overview
Journal Cancer Res
Specialty Oncology
Date 1994 Oct 1
PMID 7923112
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

The MRP gene (Cole et al., Science (Washington DC), 258: 1650-1654, 1992) encodes a membrane-bound glycoprotein the expression of which correlates with non-P-glycoprotein-mediated multidrug resistance in a variety of cultured human cell lines. Using an RNA-polymerase chain reaction assay, expression of this gene was examined in the highly chemoresistant pediatric malignancy, neuroblastoma. MRP expression was observed in 5 human neuroblastoma cell lines and in all 25 primary neuroblastoma tumors of stage I through IVS. Tumors with amplification of the N-myc oncogene were found to have significantly higher MRP expression that those with no amplification (P = 0.0016). Expression of the MRP gene in the tumor specimens was highly correlated with expression of the N-myc gene (P = 0.0009), while expression of the MDR1 gene, encoding P-glycoprotein, was not related to expression of either the N-myc or MRP genes. Decreased expression of the N-myc oncogene in neuroblastoma cell lines SH-SY5Y and BE(2)-C, following treatment with retinoic acid, was paralleled by down-regulation of MRP gene expression, contrasting with increased expression of the MDR1 gene. Expression of the MRP gene is thus common in both primary neuroblastoma tumors and cultured cell lines, and correlates with amplification and overexpression of the N-myc oncogene, which is central to the malignant phenotype of this disease.

Citing Articles

PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin.

Julson J, Quinn C, Nazam N, Bownes L, Stewart J, Beierle E J Pediatr Surg. 2024; 59(7):1334-1341.

PMID: 38570263 PMC: 11164644. DOI: 10.1016/j.jpedsurg.2024.03.014.


P2X7 receptor isoform B is a key drug resistance mediator for neuroblastoma.

Arnaud-Sampaio V, Bento C, Glaser T, Adinolfi E, Ulrich H, Lameu C Front Oncol. 2022; 12:966404.

PMID: 36091161 PMC: 9458077. DOI: 10.3389/fonc.2022.966404.


A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma.

Gamble L, Purgato S, Henderson M, Di Giacomo S, Russell A, Pigini P Cancers (Basel). 2021; 13(8).

PMID: 33918978 PMC: 8069650. DOI: 10.3390/cancers13081807.


The Expression Profiles of ADME Genes in Human Cancers and Their Associations with Clinical Outcomes.

Hu D, Mackenzie P, Nair P, McKinnon R, Meech R Cancers (Basel). 2020; 12(11).

PMID: 33202946 PMC: 7697355. DOI: 10.3390/cancers12113369.


Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future.

Liang W, Federico S, London W, Naranjo A, Irwin M, Volchenboum S JCO Clin Cancer Inform. 2020; 4:895-905.

PMID: 33058692 PMC: 7608590. DOI: 10.1200/CCI.20.00074.